" class="no-js "lang="en-US"> Avacta Archives - Medtech Alert
Wednesday, August 20, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease | MTA

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Read more

Appointments

 Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division | MTA

Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division

Avacta Group, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today […]

Clinical Trials

 Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study | PTF

Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Avacta Group, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces […]

Appointments

 Avacta Appoints Dr Christina Coughlin as Non-Executive Director | Pharmtech Focus

Avacta Appoints Dr Christina Coughlin as Non-Executive Director

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]

Clinical Trials

 Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development | Pharmtech Focus

Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]

COVID-19

 Avacta Provides Update on AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant | Pharmtech Focus

Avacta Provides Update on AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]

COVID-19

 Avacta Announces AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing | Pharmtech Focus

Avacta Announces AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]

Diseases

 Avacta Announces AffiDx SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant | Pharmtech Focus

Avacta Announces AffiDx SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful […]

Clinical Trials

 Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000 | Pharmtech Focus

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    Clinical Trials

     Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Clinical Trials

     Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

    Appointments

     Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

    News

     Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

    Clinical Trials

     Read more